Skeletal effects of parathyroid hormone (1-34) in ovariectomized rats with or without concurrent administration of salmon calcitonin.
This study evaluated the effect of parathyroid hormone (PTH) infusion alone or in combination with salmon calcitonin (sCT) in ovariectomized (OVX) rats and compared it with daily PTH injections alone or in combination with sCT infusion. Female Sprague-Dawley rats were divided randomly into 6 groups and were either bilaterally ovariectomized or underwent a sham operation; they were then treated for 4 weeks, beginning the day after surgery. Each group of OVX rats received either PTH infusion (group 1), PTH + sCT infusion (group 2), sCT infusion + daily PTH injection (group 3), or daily PTH injection (group 4). One group each of OVX (group 5) and sham-operated rats (group 6) received daily injections of vehicle alone. PTH was injected at 80 microg/kg/day and infused at 40 microg/kg/day, whereas sCT was infused at 10 microg/kg/day. The animals were sacrificed 28 days after treatment, and cancellous bone volume was measured in the tibial metaphysis. Similar to daily PTH injections, continuous infusion of PTH alone increased cancellous bone volume significantly over that seen in vehicle-treated OVX and sham-operated rats. Although cancellous bone volume after continuous infusion of PTH + sCT was also significantly higher than that seen in vehicle-treated OVX and sham-operated rats, the increase was significantly lower than with the other 3 nonvehicle treatments. The increase in cancellous bone volume after administration of sCT infusion along with daily PTH injections was not different from that with daily PTH injections alone. Thus, at the doses tested, the beneficial effects of PTH injection were not apparently improved by PTH infusion or by combination with sCT.
DeLuca
P P
PP
Faculty of Pharmaceutical Sciences, University of Kentucky, College of Pharmacy, 907 Rose Street, Lexington, KY 40536, USA. ppdelu1@pop.uky.edu
Dani
B A
BA
D000700:Analgesics / Q000008:administration & dosage; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000033:anatomy & histology / Q000187:drug effects*; D002116:Calcitonin / Q000008:administration & dosage* / Q000097:blood; D004353:Drug Evaluation, Preclinical; D005260:Female; D015918:Infusion Pumps, Implantable; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D009995:Osmosis; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000033:anatomy & histology / Q000187:drug effects
D000700:Analgesics; D010281:Parathyroid Hormone; D010446:Peptide Fragments; C028815:salmon calcitonin; D002116:Calcitonin